Single User License
INR 134840
Site License
INR 269680
Corporate User License
INR 404520

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Soft Tissue Sarcoma-Pipeline Review, H1 2015

Soft Tissue Sarcoma-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Soft Tissue Sarcoma-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Soft Tissue Sarcoma-Pipeline Review, H1 2015', provides an overview of the Soft Tissue Sarcoma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Soft Tissue Sarcoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Soft Tissue Sarcoma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Soft Tissue Sarcoma

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Soft Tissue Sarcoma and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Soft Tissue Sarcoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Soft Tissue Sarcoma pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Soft Tissue Sarcoma

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Soft Tissue Sarcoma pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Soft Tissue Sarcoma Overview 10

Therapeutics Development 11

Pipeline Products for Soft Tissue Sarcoma-Overview 11

Pipeline Products for Soft Tissue Sarcoma-Comparative Analysis 12

Soft Tissue Sarcoma-Therapeutics under Development by Companies 13

Soft Tissue Sarcoma-Therapeutics under Investigation by Universities/Institutes 18

Soft Tissue Sarcoma-Pipeline Products Glance 20

Late Stage Products 20

Clinical Stage Products 21

Early Stage Products 22

Soft Tissue Sarcoma-Products under Development by Companies 23

Soft Tissue Sarcoma-Products under Investigation by Universities/Institutes 28

Soft Tissue Sarcoma-Companies Involved in Therapeutics Development 29

A. Menarini Industrie Farmaceutiche Riunite Srl 29

Advanced Proteome Therapeutics Corporation 30

Advenchen Laboratories, LLC 31

Altor BioScience Corporation 32

Amgen Inc. 33

Bayer AG 34

Bellicum Pharmaceuticals, Inc. 35

Boehringer Ingelheim GmbH 36

CASI Pharmaceuticals Inc. 37

Celgene Corporation 38

Cellectar Biosciences, Inc. 39

CytRx Corporation 40

Daiichi Sankyo Company, Limited 41

Eisai Co., Ltd. 42

Eli Lilly and Company 43

EpiZyme, Inc. 44

Exelixis, Inc. 45

Gem Pharmaceuticals, LLC 46

Immune Design Corp. 47

Karyopharm Therapeutics, Inc. 48

Loxo Oncology, Inc. 49

MedImmune, LLC 50

Merck & Co., Inc. 51

Merrimack Pharmaceuticals, Inc. 52

Mirati Therapeutics Inc. 53

MolMed S.p.A. 54

Morphotek, Inc. 55

Nanobiotix 56

Neotropix, Inc. 57

Novartis AG 58

Oncos Therapeutics Ltd. 59

Onxeo SA 60

Pfizer Inc. 61

Pharma Mar, S.A. 62

Plexxikon Inc. 63

Polaris Pharmaceuticals, Inc. 64

Recombio S.L 65

Rigontec GmbH 66

Sanofi 67

Shionogi & Co., Ltd. 68

Siena Biotech S.p.A. 69

Sigma-Tau S.p.A. 70

Sumitomo Dainippon Pharma Co., Ltd. 71

Threshold Pharmaceuticals, Inc. 72

TRACON Pharmaceuticals, Inc. 73

Vicore Pharma AB 74

Soft Tissue Sarcoma-Therapeutics Assessment 75

Assessment by Monotherapy Products 75

Assessment by Combination Products 76

Assessment by Target 77

Assessment by Mechanism of Action 82

Assessment by Route of Administration 86

Assessment by Molecule Type 88

Drug Profiles 90

afatinib-Drug Profile 90

AL-3818-Drug Profile 94

aldoxorubicin hydrochloride-Drug Profile 96

ALT-836-Drug Profile 99

APC-103-Drug Profile 101

belinostat-Drug Profile 102

BI-853520-Drug Profile 105

C-21-Drug Profile 106

cabazitaxel-Drug Profile 108

cabozantinib s-malate-Drug Profile 110

cancer vaccine-Drug Profile 113

Cell Therapy 2 for Oncology and Infectious Disease-Drug Profile 114

Cell Therapy for GD2 Expressing Solid Tumors-Drug Profile 115

Cell Therapy to Target LMP-1 and LMP-2 for Oncology-Drug Profile 116

Cell Therapy to Target LMP-1 and LMP-2 for Oncology and Infectious Diseases-Drug Profile 117

celyvir-Drug Profile 118

Dendritic Cell Therapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology-Drug Profile 120

Dendritic Cells + Cytokine Induced Killer Cells-Drug Profile 121

DSR-6434-Drug Profile 122

durvalumab + tremelimumab-Drug Profile 123

E-6438-Drug Profile 125

efatutazone-Drug Profile 127

ENMD-2076-Drug Profile 129

eribulin mesylate-Drug Profile 131

everolimus-Drug Profile 135

evofosfamide-Drug Profile 140

G-100-Drug Profile 148

ganitumab-Drug Profile 149

GPX-150-Drug Profile 152

I131-CLR1404-Drug Profile 155

ImOl-100-Drug Profile 157

irinotecan sucrosofate liposomal-Drug Profile 158

KRA-0008-Drug Profile 161

LK-3-Drug Profile 162

LOXO-101-Drug Profile 163

mocetinostat-Drug Profile 165

MVXONCO-1-Drug Profile 168

NBTX-TOPO-Drug Profile 169

NBTXR-3-Drug Profile 170

NGR-hTNF-Drug Profile 172

NOV-110501-Drug Profile 176

NTX-010-Drug Profile 177

olaratumab-Drug Profile 179

ONCOS-102-Drug Profile 181

ontuxizumab-Drug Profile 182

paclitaxel albumin bound-Drug Profile 184

palbociclib-Drug Profile 187

panobinostat-Drug Profile 191

pazopanib hydrochloride-Drug Profile 197

pembrolizumab-Drug Profile 202

Peptide to Target COX-2 and MAS-GPCR for Oncology-Drug Profile 209

PLX-7486-Drug Profile 211

regorafenib-Drug Profile 212

ribociclib-Drug Profile 215

S-588410-Drug Profile 218

sabarubicin-Drug Profile 219

selinexor-Drug Profile 221

SEN-461-Drug Profile 226

SST-0001-Drug Profile 227

talimogene laherparepvec-Drug Profile 228

TNF-PEG 20-Drug Profile 231

trabectedin-Drug Profile 232

TRC-105-Drug Profile 236

vorinostat-Drug Profile 239

Soft Tissue Sarcoma-Recent Pipeline Updates 243

Soft Tissue Sarcoma-Dormant Projects 366

Soft Tissue Sarcoma-Discontinued Products 371

Soft Tissue Sarcoma-Product Development Milestones 372

Featured News & Press Releases 372

Appendix 381

Methodology 381

Coverage 381

Secondary Research 381

Primary Research 381

Expert Panel Validation 381

Contact Us 381

Disclaimer 382

List of Tables

Number of Products under Development for Soft Tissue Sarcoma, H1 2015 15

Number of Products under Development for Soft Tissue Sarcoma-Comparative Analysis, H1 2015 16

Number of Products under Development by Companies, H1 2015 18

Number of Products under Development by Companies, H1 2015 (Contd..1) 19

Number of Products under Development by Companies, H1 2015 (Contd..2) 20

Number of Products under Development by Companies, H1 2015 (Contd..3) 21

Number of Products under Investigation by Universities/Institutes, H1 2015 23

Comparative Analysis by Late Stage Development, H1 2015 24

Comparative Analysis by Clinical Stage Development, H1 2015 25

Comparative Analysis by Early Stage Development, H1 2015 26

Products under Development by Companies, H1 2015 27

Products under Development by Companies, H1 2015 (Contd..1) 28

Products under Development by Companies, H1 2015 (Contd..2) 29

Products under Development by Companies, H1 2015 (Contd..3) 30

Products under Development by Companies, H1 2015 (Contd..4) 31

Products under Investigation by Universities/Institutes, H1 2015 32

Soft Tissue Sarcoma-Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H1 2015 33

Soft Tissue Sarcoma-Pipeline by Advanced Proteome Therapeutics Corporation, H1 2015 34

Soft Tissue Sarcoma-Pipeline by Advenchen Laboratories, LLC, H1 2015 35

Soft Tissue Sarcoma-Pipeline by Altor BioScience Corporation, H1 2015 36

Soft Tissue Sarcoma-Pipeline by Amgen Inc., H1 2015 37

Soft Tissue Sarcoma-Pipeline by Bayer AG, H1 2015 38

Soft Tissue Sarcoma-Pipeline by Bellicum Pharmaceuticals, Inc., H1 2015 39

Soft Tissue Sarcoma-Pipeline by Boehringer Ingelheim GmbH, H1 2015 40

Soft Tissue Sarcoma-Pipeline by CASI Pharmaceuticals Inc., H1 2015 41

Soft Tissue Sarcoma-Pipeline by Celgene Corporation, H1 2015 42

Soft Tissue Sarcoma-Pipeline by Cellectar Biosciences, Inc., H1 2015 43

Soft Tissue Sarcoma-Pipeline by CytRx Corporation, H1 2015 44

Soft Tissue Sarcoma-Pipeline by Daiichi Sankyo Company, Limited, H1 2015 45

Soft Tissue Sarcoma-Pipeline by Eisai Co., Ltd., H1 2015 46

Soft Tissue Sarcoma-Pipeline by Eli Lilly and Company, H1 2015 47

Soft Tissue Sarcoma-Pipeline by EpiZyme, Inc., H1 2015 48

Soft Tissue Sarcoma-Pipeline by Exelixis, Inc., H1 2015 49

Soft Tissue Sarcoma-Pipeline by Gem Pharmaceuticals, LLC, H1 2015 50

Soft Tissue Sarcoma-Pipeline by Immune Design Corp., H1 2015 51

Soft Tissue Sarcoma-Pipeline by Karyopharm Therapeutics, Inc., H1 2015 52

Soft Tissue Sarcoma-Pipeline by Loxo Oncology, Inc., H1 2015 53

Soft Tissue Sarcoma-Pipeline by MedImmune, LLC, H1 2015 54

Soft Tissue Sarcoma-Pipeline by Merck & Co., Inc., H1 2015 55

Soft Tissue Sarcoma-Pipeline by Merrimack Pharmaceuticals, Inc., H1 2015 56

Soft Tissue Sarcoma-Pipeline by Mirati Therapeutics Inc., H1 2015 57

Soft Tissue Sarcoma-Pipeline by MolMed S.p.A., H1 2015 58

Soft Tissue Sarcoma-Pipeline by Morphotek, Inc., H1 2015 59

Soft Tissue Sarcoma-Pipeline by Nanobiotix, H1 2015 60

Soft Tissue Sarcoma-Pipeline by Neotropix, Inc., H1 2015 61

Soft Tissue Sarcoma-Pipeline by Novartis AG, H1 2015 62

Soft Tissue Sarcoma-Pipeline by Oncos Therapeutics Ltd., H1 2015 63

Soft Tissue Sarcoma-Pipeline by Onxeo SA, H1 2015 64

Soft Tissue Sarcoma-Pipeline by Pfizer Inc., H1 2015 65

Soft Tissue Sarcoma-Pipeline by Pharma Mar, S.A., H1 2015 66

Soft Tissue Sarcoma-Pipeline by Plexxikon Inc., H1 2015 67

Soft Tissue Sarcoma-Pipeline by Polaris Pharmaceuticals, Inc., H1 2015 68

Soft Tissue Sarcoma-Pipeline by Recombio S.L, H1 2015 69

Soft Tissue Sarcoma-Pipeline by Rigontec GmbH, H1 2015 70

Soft Tissue Sarcoma-Pipeline by Sanofi, H1 2015 71

Soft Tissue Sarcoma-Pipeline by Shionogi & Co., Ltd., H1 2015 72

Soft Tissue Sarcoma-Pipeline by Siena Biotech S.p.A., H1 2015 73

Soft Tissue Sarcoma-Pipeline by Sigma-Tau S.p.A., H1 2015 74

Soft Tissue Sarcoma-Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2015 75

Soft Tissue Sarcoma-Pipeline by Threshold Pharmaceuticals, Inc., H1 2015 76

Soft Tissue Sarcoma-Pipeline by TRACON Pharmaceuticals, Inc., H1 2015 77

Soft Tissue Sarcoma-Pipeline by Vicore Pharma AB, H1 2015 78

Assessment by Monotherapy Products, H1 2015 79

Assessment by Combination Products, H1 2015 80

Number of Products by Stage and Target, H1 2015 82

Number of Products by Stage and Mechanism of Action, H1 2015 87

Number of Products by Stage and Route of Administration, H1 2015 91

Number of Products by Stage and Molecule Type, H1 2015 93

Soft Tissue Sarcoma Therapeutics-Recent Pipeline Updates, H1 2015 247

Soft Tissue Sarcoma-Dormant Projects, H1 2015 370

Soft Tissue Sarcoma-Dormant Projects (Contd..1), H1 2015 371

Soft Tissue Sarcoma-Dormant Projects (Contd..2), H1 2015 372

Soft Tissue Sarcoma-Dormant Projects (Contd..3), H1 2015 373

Soft Tissue Sarcoma-Dormant Projects (Contd..4), H1 2015 374

Soft Tissue Sarcoma-Discontinued Products, H1 2015 375

List of Figures

Number of Products under Development for Soft Tissue Sarcoma, H1 2015 15

Number of Products under Development for Soft Tissue Sarcoma-Comparative Analysis, H1 2015 16

Number of Products under Development by Companies, H1 2015 17

Number of Products under Investigation by Universities/Institutes, H1 2015 22

Comparative Analysis by Late Stage Development, H1 2015 24

Comparative Analysis by Clinical Stage Development, H1 2015 25

Comparative Analysis by Early Stage Products, H1 2015 26

Assessment by Monotherapy Products, H1 2015 79

Number of Products by Top 10 Targets, H1 2015 81

Number of Products by Stage and Top 10 Targets, H1 2015 81

Number of Products by Top 10 Mechanism of Actions, H1 2015 86

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 86

Number of Products by Top 10 Routes of Administration, H1 2015 90

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 91

Number of Products by Top 10 Molecule Types, H1 2015 92

Number of Products by Stage and Top 10 Molecule Types, H1 2015 93

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

A. Menarini Industrie Farmaceutiche Riunite Srl

Advanced Proteome Therapeutics Corporation

Advenchen Laboratories, LLC

Altor BioScience Corporation

Amgen Inc.

Bayer AG

Bellicum Pharmaceuticals, Inc.

Boehringer Ingelheim GmbH

CASI Pharmaceuticals Inc.

Celgene Corporation

Cellectar Biosciences, Inc.

CytRx Corporation

Daiichi Sankyo Company, Limited

Eisai Co., Ltd.

Eli Lilly and Company

EpiZyme, Inc.

Exelixis, Inc.

Gem Pharmaceuticals, LLC

Immune Design Corp.

Karyopharm Therapeutics, Inc.

Loxo Oncology, Inc.

MedImmune, LLC

Merck & Co., Inc.

Merrimack Pharmaceuticals, Inc.

Mirati Therapeutics Inc.

MolMed S.p.A.

Morphotek, Inc.

Nanobiotix

Neotropix, Inc.

Novartis AG

Oncos Therapeutics Ltd.

Onxeo SA

Pfizer Inc.

Pharma Mar, S.A.

Plexxikon Inc.

Polaris Pharmaceuticals, Inc.

Recombio S.L

Rigontec GmbH

Sanofi

Shionogi & Co., Ltd.

Siena Biotech S.p.A.

Sigma-Tau S.p.A.

Sumitomo Dainippon Pharma Co., Ltd.

Threshold Pharmaceuticals, Inc.

TRACON Pharmaceuticals, Inc.

Vicore Pharma AB

Soft Tissue Sarcoma Therapeutic Products under Development, Key Players in Soft Tissue Sarcoma Therapeutics, Soft Tissue Sarcoma Pipeline Overview, Soft Tissue Sarcoma Pipeline, Soft Tissue Sarcoma Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com